Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
- 15 September 2015
- journal article
- other
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 29 (12), 2449-2451
- https://doi.org/10.1038/leu.2015.220
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsBlood, 2015
- Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registryLeukemia, 2015
- The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the NetherlandsLeukemia Research, 2015
- Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010European Journal of Cancer, 2014
- A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialHaematologica, 2013
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromesCancer, 2011
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Completeness of Cancer Registration in Limburg, the NetherlandsInternational Journal of Epidemiology, 1993